Results: 10
Suicide risk and antidepressants: beyond the controversy.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 179, doi. 10.1002/ddr.20021
- By:
- Publication type:
- Article
The pharmacogenetics of antidepressant treatments for depressive disorders.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 170, doi. 10.1002/ddr.20020
- By:
- Publication type:
- Article
Protein kinase C substrate activators: potential as novel antidepressants.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 156, doi. 10.1002/ddr.20019
- By:
- Publication type:
- Article
Mood disorders and their treatment: alterations in the regulation of receptor‐G protein coupling.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 147, doi. 10.1002/ddr.20018
- By:
- Publication type:
- Article
5‐HT1B receptor: a target for antidepressant drugs?
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 141, doi. 10.1002/ddr.20017
- By:
- Publication type:
- Article
5‐HT2 receptors and anxiety.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 133, doi. 10.1002/ddr.20016
- By:
- Publication type:
- Article
Histamine receptors as potential therapeutic targets to treat anxiety and depression.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 126, doi. 10.1002/ddr.20015
- By:
- Publication type:
- Article
The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 119, doi. 10.1002/ddr.20014
- By:
- Publication type:
- Article
Monoamine reuptake inhibitors: highlights of recent research developments.
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 97, doi. 10.1002/ddr.20013
- By:
- Publication type:
- Article
New drug targets for depression and anxiety: Is the peptides era arriving?
- Published in:
- Drug Development Research, 2005, v. 65, n. 3, p. 93, doi. 10.1002/ddr.20012
- By:
- Publication type:
- Article